Brief: Kane Biotech Reports Qtrly Loss Per Share (Post Consolidation) $0.011
17/05/2018 22:34
May 17 (Reuters) - Kane Biotech Inc KNE.V :
* KANE BIOTECH ANNOUNCES FIRST QUARTER 2018 FINANCIAL
RESULTS,
GRANTING OF OPTIONS AND INVESTOR RELATIONS IMPROVEMENTS
* KANE BIOTECH INC QTRLY LOSS PER SHARE (POST CONSOLIDATION)
$0.011
Source text for Eikon: ID:nGNX7v2Xf8
Further company coverage: KNE.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kane Biotech
See all newsBrief: Kane Biotech Announces FDA 510(K) Clearance For Revyve® Antimicrobial Skin And Wound Cleanser
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update